Sensus Healthcare, Inc. is a medical device company that is engaged in the development and delivery of non-invasive treatments for skin cancer and keloids. The Company, leveraging its superficial radiotherapy (SRT and IG-SRT) technology, provides healthcare providers with a patient-centric treatment platform. Its products and services include SRT-100, SRT-100 Vision, SRT-100+, Sentinel service program and others. The SRT-100 is a photon x-ray low energy SRT system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides customers with additional options compared to the SRT-100 base model. These additional options allow for dedicated treatment planning and full treatment progression documentation in a patient’s record. The SRT-100+ offers all the same features as the SRT-100, with the addition of remote diagnostics and other features.
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 27.48M.
Virada para Prejuízo
O desempenho da empresa passou a ser negativo, com prejuízo anual mais recente de US$ .
Avaliação Justa
O PE mais recente da empresa é -6.46, em uma faixa percentil média de 3 anos.
Venda Institucional
As participações institucionais mais recentes são de 5.57M ações, uma redução de 10.32% em relação ao trimestre anterior.
Mantido por James Simons
O Super Investidor James Simons possui 0.00 ações desta empresa.